

Journal section: *Periodontology*
 Publication Types: *Review*

doi:10.4317/medoral.23166
<https://dx.doi.org/doi:10.4317/medoral.23166>

Hematopoietic and lymphatic cancers in patients with periodontitis: a systematic review and meta-analysis

Yongen Wu ¹, Xiaojun Shi ², Yinghua Li ³, Ju Xia ¹, Yuting Gu ¹, Qingqing Qian ^{1,4}, Yang Hong ^{1,5}

¹ National Institute of Clinical Research, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China

² Department of Stomatology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, 200240, China

³ Central Laboratory, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China

⁴ Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China

⁵ Department of Osteology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China

Correspondence:

National Institute of Clinical Research
 The Fifth People's Hospital of Shanghai, Fudan University
 128 Ruili Road, Minhang District
 Shanghai 200240, China
wu05055225@126.com

Received: 22/04/2019
 Accepted: 16/09/2019

Wu Y, Shi X, Li Y, Xia Ju, Gu Y, Qian Q, *et al.* Hematopoietic and lymphatic cancers in patients with periodontitis: a systematic review and meta-analysis. *Med Oral Patol Oral Cir Bucal.* 2020 Jan 1;25 (1):e21-8.
http://www.medicinaoral.com/pubmed/medoralv25_i1_p21.pdf

Article Number: 23166 <http://www.medicinaoral.com/>
 © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
 eMail: medicina@medicinaoral.com
Indexed in:
 Science Citation Index Expanded
 Journal Citation Reports
 Index Medicus, MEDLINE, PubMed
 Scopus, Embase and Emcare
 Índice Médico Español

Abstract

Background: Numerous studies have explored the correlation of periodontal disease (PD) with risk of hematopoietic and lymphatic cancers, but the findings were inconsistent. Therefore, we did a meta-analysis to ascertain the correlation of PD with risk of incident hematopoietic and lymphatic cancers.

Material and Methods: The authors searched relevant studies in databases (PubMed, Web of Science, and MEDLINE). The summary relative risk (RR) along with 95% confidence interval (CI) was calculated by use of random or fixed effects models.

Results: Six studies were included in qualitative synthesis. The pooled analysis revealed that PD was significantly associated with an increased risk of hematopoietic and lymphatic cancers (RR = 1.17; 95% CI = 1.07–1.27; $P = 0$). Stratified analysis showed the association of PD with hematopoietic and lymphatic cancers remained significant in the never smokers (RR = 1.28; 95% CI = 1.07–1.54; $P = 0.007$), and in the American population (RR = 1.17; 95% CI = 1.05–1.30; $P = 0.003$), respectively.

Conclusion: Never smokers population and the American population with PD have a higher risk of developing hematopoietic and lymphatic cancers. PD might be considered as a risk factor for hematopoietic and lymphatic cancers.

Key words: *Periodontal disease, hematopoietic and lymphatic cancer, meta-analysis, systematic review.*

Introduction

PD is a chronic inflammatory condition that affects the tissues surrounding the teeth, including alveolar bone, cementum, periodontal ligament and gingival. If periodontitis remains untreated, it may lead to annihilation of periodontium, tooth looseness and ultimately tooth loss. PD has been reported to increase the risk of chronic diseases, such as diabetes, cardiovascular disease, rheumatoid arthritis, and pulmonary disease (1-5). Furthermore, increasing evidence indicates that people with periodontitis may be at higher risk of developing oral cancers (6), cancer of head and neck (7-8), esophagus (9), lung (4), pancreas (10), colorectum (11), and breast (12). Additionally, greater number of tooth loss might increase the risk of developing cancer in patients. Hematopoietic and lymphatic malignancies are cancers that affect blood, lymphatic system, and bone marrow. There are a number of risk factors associated with lymphoma (Hodgkin lymphoma, non-Hodgkin lymphoma), such as age, gender, Epstein-Barr infection, and immune dysregulation (<https://www.cancer.gov/types/lymphoma>). The most common risk factors associated with hematopoietic cancers (acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma) include older age, smoking, prior chemotherapy, and exposure to radiation (<https://www.cancer.gov/types/leukemia>).

Recently, numerous epidemiological studies exploring the risk of hematopoietic and lymphatic cancers in patients with periodontitis have been published (13-19). However, these studies showed inconsistent results and the evidence remained inclusive. Therefore, we aimed to systematically evaluate the published literature and to quantify the association of periodontitis with risk of hematopoietic and lymphatic cancers via meta-analysis.

Material and Methods

- Literature and search strategy

We followed the instructions of the PRISMA to conduct this meta-analysis (20). The focused question followed the PECO (population, exposure, comparison, outcomes) criteria: The population (P) was patients of any age; the exposure (E) was the presence of periodontal diseases (PDs); the comparison (C) was the absence of PDs; and the outcomes (O) were patients diagnosed with hematopoietic or lymphatic cancers.

PubMed, Web of Science, and MEDLINE were systematically searched to identify potentially eligible studies that assessed the correlation of PDs with hematopoietic and lymphatic cancers. We used the search terms: (“periodontal diseases” or periodontitis or gingivitis or “tooth loss” or “teeth loss”) and (hematological or haematological or hematologic or hematopoietic or lymphatic or lymphomas or lymphoma or lymphoid) and

(cancers or malignancies). The search was completed on 31 Oct 2018.

- Selection criteria, data extraction and quality assessment
Published studies that estimated the relative risk of hematopoietic and lymphatic cancers associated with any measure of PD (i.e. periodontitis, gingivitis) were eligible. Comments, review articles and meta-analysis were excluded.

The following data from each included study were independently extracted by two investigators (YGW and XJS). The relevant data included first author of the study, year of publication, country of origin, study design, sample sizes in each group, age, gender, cancer type, duration of follow-up, exposure, relative risk (RR), hazards ratios (HR), or odds ratio (OR) estimates with 95%CI for outcomes.

The quality of included studies was assessed according to the Newcastle-Ottawa Scale (NOS) (21). This scale consists of assessment of three parts: selection (0-4 points), comparability (0-2 points), and outcome/exposure (0-3 points) for a total score of 9 points. In the NOS, poor, moderate, and high quality was scored 0–3, 4–6, and 7–9, respectively.

- Statistical analysis

Relative risk (RR) with 95% confidence interval (CI) was used as the common measure of association across studies. RR was calculated by the formula $RR = \frac{\text{event/total}_{\text{exposure}}}{\text{event/total}_{\text{non-exposure}}}$, in which $\text{event/total}_{\text{exposure}}$ and $\text{event/total}_{\text{non-exposure}}$ is the incidence of an outcome of interest in the exposed group and non-exposed group, respectively. HR was considered equivalent to RR when pooled in qualitative synthesis. When the incidence of outcome is more than 10% in a cohort study, the OR was transformed into RR with this formula: $RR = OR / [(1 - P_0) + (P_0 \times OR)]$, in which P_0 is the incidence of the outcome of interest in the non-exposed group (22). The standard error (SE) of the converted RR was determined with this formula: $SE_{\log(RR)} = SE_{\log(OR)} \times \log(RR) / \log(OR)$ (23).

Heterogeneity across studies was evaluated using the Q statistic ($P < 0.10$ was regarded as statistical significance) and was quantified with I^2 statistic. I^2 values higher than 50% indicated moderate heterogeneity. In the presence of heterogeneity ($P < 0.10$), we combined the effect estimates across studies by use of a random-effects model (24); otherwise, the fixed effect model was adopted (25). The potential heterogeneity across studies was explored by subgroup analysis and sensitivity analysis. Sensitivity analysis was conducted via deleting each study at a time and calculating the summary effect size of the remaining studies. The funnel plots as well as Egger regression test were applied to assess publication bias (26). We used STATA 14.0 (Stata Corporation, College Station, TX, U.S.A.) for data analysis. Two-sided $P < 0.05$ was regarded as statistically significant.

Results

- Literature retrieved and study characteristics

A total of 853 articles were initially identified and assessed. Fig. 1 showed the detailed flow diagram of the exclusion and inclusion process. Two articles used the same dataset so the more comprehensive analysis by Bertrand *et al.* (16) was included and the study by Michaud *et al.* (27) was excluded from the quantitative synthesis. The study by Dizdar *et al.* was excluded for poor quality. The study by WEN *et al.* (28) was also excluded because of ineligible comparator. Six articles ultimately were eligible for inclusion and were included in qualitative synthesis (13-18). Five of the six studies were cohort studies (14-18), and one study (13) was case-control study.

Table 1 summarized the detailed characteristics of included studies reporting risk estimates for the correlation of PD with hematopoietic and lymphatic cancers. Quality assessment of the included studies according to the NOS is shown in Table 2 and Table 3. All of the six studies were of high quality scoring ≥ 7 .




Fig. 1: Flow diagram for study selection in this meta-analysis.

Table 1: Characteristics of studies on the association of periodontal disease with hematopoietic and lymphatic cancers.

First author	Country (year)	Study design	Exposure (event/total)	No-exposure (event/total)	Age (yrs)	Gender	Cancer type	Time periods	Exposure	Estimate (s) (95% confidence interval, CI)	Adjusted factors
Kristinsson <i>et al.</i> (13)	Sweden (2010)	Case-control	3/26	644/3161	19-98	Female and male	Lymphoplasmacytic lymphoma	1958-2005	Gingivitis and periodontitis vs. no gingivitis and periodontitis	OR: 0.6 (0.2, 2.0) Converted RR: 0.65 (0.21, 2.06)	Year of birth, date of diagnosis, gender, and county.
Chung <i>et al.</i> (14)	China (2015)	Retropective cohort	87/40140	75/40140	≥ 40	Female and male	Hematopoietic and lymphatic cancer	2002-2009	Periodontitis vs. no periodontitis	HR: 1.18 (1.02, 1.37)	Age, gender, urbanization level, monthly income, geographic region and diabetes
Mai <i>et al.</i> (15)	USA (2016)	Pro-spective cohort	8/665	5/315	53-85	Female	Hematopoietic and lymphatic cancer	1997-2014	Mild/moderate periodontitis vs. no periodontitis	HR: 0.72 (0.23, 2.26)	Age and smoking
			11/357	5/315					Severe periodontitis vs. no periodontitis	HR: 2.09 (0.68, 6.47)	Age and smoking
			19/1022	5/315					Periodontitis vs. no periodontitis	RR: 1.17 (0.44, 3.10)	
Bertrand <i>et al.</i> (16)	USA (2017) USA (2017)	Pro-spective cohort	262/7496	613/38651	40-75	Male	Non-Hodgkin lymphoma	1986-2012	Periodontitis vs. no periodontitis	HR: 1.30 (1.11, 1.51)	Age, race, diabetes history and BMI
			47/2249	298/19326						HR ^a : 1.16 (0.83, 1.61)	
			123/3973	363/16233						HR ^b : 1.31 (1.05, 1.63)	
			14/1274	30/3479						HR ^c : 2.59 (1.05, 6.35)	
			174/6821	660/36332						HR ^d : 1.29 (1.08, 1.54)	Missing teeth, diabetes, smoking history, and BMI
10/675	31/2319	HR ^e : 0.81 (0.31, 2.15)	Missing teeth, diabetes, smoking history, and BMI								

Table 1 cont.: Characteristics of studies on the association of periodontal disease with hematopoietic and lymphatic cancers.

Nwizu <i>et al.</i> (17)	USA (2017)	Pro-spective cohort	229/17103	591/48766	54-86	Female	Hemato-poietic and lymphatic cancer	1999-2013	Periodontitis vs. no periodontitis	HR: 1.11 (0.95, 1.30)	Age, smoking and BMI	
			112/7245	307/26852						HR ^a : 1.34 (1.08, 1.67)		
			111/8811	268/20200						HR ^b : 0.96 (0.77, 1.19)		
			6/1047	16/1714							HR ^c : 0.60 (0.24, 1.55)	Age and BMI
			121/17103	321/48766						HR: 1.08 (0.87, 1.34)	Age, smoking and BMI	
			36/17103	105/48766						HR: 1.05 (0.72, 1.54)	Age, smoking and BMI	
			66/17103	168/48766						HR: 1.10 (0.83, 1.47)	Age, smoking and BMI	
Michaud <i>et al.</i> (18)	USA (2018)	Pro-spective cohort	7/710	36/1710	44-66	Female and male	Hemato-poietic and lymphatic cancer	1987-2012	Mild periodontitis vs. no periodontitis	HR: 0.46 (0.20, 1.06)	Age, education level, smoking, drinking status, BMI, and diabetes	
			44/2514	36/1710					Moderate periodontitis vs. no periodontitis	HR: 0.77 (0.49, 1.22)		
			24/1122	36/1710					Severe periodontitis vs. no periodontitis	HR: 0.89 (0.52, 1.52)		
			18/1410	36/1710					Edentulism vs. no periodontitis	HR: 0.61 (0.33, 1.12)		
			75/4346	36/1710					Periodontitis vs. no periodontitis	RR: 0.82 (0.56, 1.22)		
			61/3625	26/1228					Periodontitis vs. no periodontitis	RR ^d : 0.80 (0.51, 1.26)		
			14/721	10/484					Periodontitis vs. no periodontitis	RR ^e : 0.94 (0.42, 2.10)		

Abbreviations: OR, odds ratios; RR, relative risk; HR, hazard ratio; BMI, body mass index.

^aNever smokers, ^bPast smokers, ^cCurrent smokers, ^dWhite, ^eNon-White.

Table 2: Quality assessment of cohort studies according to the Newcastle-Ottawa scale.

First author	Selection				Comparability		Outcome			Total quality scores
	1. Exposed cohort truly or somewhat representative of community	2. Non-exposed cohort drawn from the same community as the exposed cohort	3. Secure record/ structured interview to ascertain exposure	4. Outcome of interest not present at start of study	1. Study controls for the most important factor	2. Study controls for any additional factor	1. Independent blind assessment/ record linkage to assess the outcome	2. Follow-up long enough for outcome of interest	3. Adequacy of follow-up of the two cohorts	
Chung <i>et al.</i> (14)	*	*	-	-	*	*	*	*	*	7
Mai <i>et al.</i> (15)	*	*	*	*	*	-	*	*	*	8
Bertrand <i>et al.</i> (16)	*	*	-	*	*	*	*	*	*	8
Nwizu <i>et al.</i> (17)	*	*	-	*	*	-	*	*	*	7
Michaud <i>et al.</i> (18)	*	*	*	*	*	*	*	*	*	9

Asterisk means that the item is satisfied.

Table 3: Quality assessment of case-control studies according to the Newcastle-Ottawa scale.

First author	Selection				Comparability		Exposure			Total quality scores
	1. Case definition is adequate	2. Consecutive or obviously representative series of cases	3. Community controls	4. No history of disease (end-point) in controls	1. Study controls for the most important factor	2. Study controls for any additional factor	1. Secure record/structured interview blind to case/control status	2. Same method for ascertainment for cases and controls	3. Non-response rate same for both groups	
Kristinsson <i>et al.</i> (13)	*	*	*	*	*	*	-	*	-	7

Asterisk means that the item is satisfied.

- Overall estimates and subgroup analysis

Pooled results showed that subjects with PD have an increased risk for hematopoietic and lymphatic cancers (RR = 1.17; 95% CI 1.07–1.27; $P = 0$). No evidence of heterogeneity was observed ($P = 0.263$; $I^2 = 22.7\%$; Fig. 2). Table 4 showed the results of subgroup analysis by study type, study design, smoking status, gender, country origin, ethnicity, and stage of PD. Results of the subgroup analyses based on cancer types indicated that

patients with PD increased the risk of lymphatic cancers (RR = 1.21; 95% CI = 1.07–1.37), while the risk of hematopoietic cancers was not significant (RR = 1.08; 95% CI = 0.86–1.36). Subgroup analyses according to study design revealed significant relation of PD with increased risk of hematopoietic and lymphatic cancers in prospective cohort studies (RR = 1.17; 95% CI = 1.05–1.30) and in retrospective studies (RR = 1.17; 95% CI = 1.01–1.35).

Table 4: Results of subgroup analyses of pooled relative risk (RR) and 95% confidence interval (CI).

Subgroup analyses	No. of studies	RR (95%CI)	p	P of heterogeneity	I ² (%)
Overall	6	1.17 (1.07, 1.27)	0	0.263	22.7%
Cancer types					
Hematopoietic cancers	2	1.08 (0.86, 1.36)	0.501	0.848	0.0%
Lymphatic cancers	3	1.21 (1.07, 1.37)	0.002	0.219	34.1%
Study design					
Prospective cohort	4	1.17 (1.05, 1.30)	0.003	0.143	44.8%
Retrospective cohort or case-control	2	1.17 (1.01, 1.35)	0.037	0.31	3.0%
Smoking status					
Never smokers	2	1.28 (1.07, 1.54)	0.007	0.476	0.0%
Past smokers	2	1.12 (0.83, 1.52)	0.463	0.049	74.2%
Current smokers	2	1.25 (0.30, 5.25)	0.758	0.027	79.6%
Gender					
Male and female	3	1.12 (0.98, 1.28)	0.109	0.148	47.6%
Female	2	1.11 (0.95, 1.30)	0.181	0.917	0.0%
Male	1	1.30 (1.11, 1.52)	0.001	NA	NA
Country origin					
Asia	1	1.18 (1.02, 1.37)	0.028	NA	NA
USA	4	1.17 (1.05, 1.30)	0.003	0.143	44.8%
Europe	1	0.65 (0.21, 2.04)	0.46	NA	NA
Ethnicity					
White	2	1.07 (0.67, 1.68)	0.788	0.054	73.1%
Non-White	2	0.88 (0.48, 1.64)	0.698	0.817	0.0%
Stage of periodontal disease					
Mild/moderate vs. none	3	0.69 (0.47, 1.00)	0.052	0.567	0.0%
Severe/edentulism vs. none	3	0.85 (0.58, 1.24)	0.393	0.104	44.6%

Abbreviations: NA, not available.




Fig. 2: Forest plot for periodontal disease associated with hematopoietic and lymphatic cancers risk. The relative risk with 95% confidence interval for each study is represented by the square and horizontal line, respectively. The diamonds show the estimated pooled relative risk with corresponding 95% confidence interval.

Analyses stratified by smoking status showed that PD was associated with risk of hematopoietic and lymphatic cancers among never smokers (RR = 1.28; 95% CI = 1.07–1.54) but not among past (RR = 1.12; 95% CI = 0.83–1.52) or current smokers (RR = 1.25; 95% CI = 0.30–5.25). A gender-specific analysis showed that the association between PD and risk of hematopoietic and lymphatic cancers was not statistically significant in male and female population (summary RR = 1.12; 95% CI = 0.98–1.28), and female population (pooled RR = 1.11; 95% CI = 0.95–1.30), respectively. Four studies were performed in America, one in Asia, and one in Europe. For subgroup analysis by geographic region, the significant association between PD and risk of hematopoietic and lymphatic cancers was observed among the American population (RR = 1.17; 95% CI = 1.05–1.30). Stratification analysis by ethnicity demonstrated no significant association between PD and risk of hematopoietic and lymphatic cancers in the white population or non-white population. Moreover, pooled estimates found no evidence of increased risk of hematopoietic and lymphatic cancers among individuals with mild/moderate PD (RR = 0.69; 95% CI = 0.47–1.00) and severe/edentulous PD (RR = 0.85; 95% CI = 0.58–1.24), respectively.

- Sensitivity analyses

In sensitivity analysis using the leave-one-out approach, the results showed that no individual study significantly altered the pooled RR for PD on hematopoietic and lymphatic cancers risk, with pooled RR varying from 1.12 (95% CI, 1.01–1.24) to 1.20 (95% CI, 1.08–1.32), demonstrating the meta-analysis results were robust (Figure not shown).

- Bias assessment

To examine the extent of publication bias for included studies, funnel plot and Egger regression analysis were conducted. The funnel plot on included studies showed a little asymmetry (Fig. 3). The Egger regression analysis was not significant for publication bias across studies (P = 0.224).




Fig. 3: Funnel plot to assess publication bias. Each point indicates individual studies included in the meta-analysis.

Discussion

The results on the association between PD and the risk of hematopoietic and lymphatic cancer are less consistent. No associations were detected in four of the six included studies (13,15,17,18), but two studies reported a higher risk of hematopoietic and lymphatic cancer among participants with PD (14,16). The qualitative synthesis results indicated that PD was significantly associated with increased risk of hematopoietic and lymphatic cancers, especially lymphatic cancers, which is in agreement with previous report (19).

The underlying mechanisms behind the potential association are as follows: first, PD may increase cancer risk through the chronic release of inflammatory mediators or immune system dysregulation (29-32). Second, PD may influence carcinogenesis via the increased exposure to carcinogenic nitrosamines (33). PD and poor dental hygiene were shown to enhance the formation of nitrosamines and oral bacteria in the oral cavity (34). Thus, anti-inflammation treatments for PD reduce markers of systemic inflammation and may decrease subsequent cancer risks. However, Hwang *et al.* found that anti-inflammation therapies of PD did not reduce the risk of hematopoietic and lymphatic cancers (35).

Tooth loss is often the result of severe periodontitis. Moreover, tooth loss was found to be positively associated with risk of certain cancers such as head and neck, esophageal, and lung cancers (34). A dose-response meta-analysis revealed that each ten-tooth loss was associated with a 3% increment of risk of hematopoietic cancer (36).

Our meta-analysis has several potential limitations. First, although most included studies have adjusted for common covariates, other unmeasured confounding factors such as socioeconomic status, stress, along with genetics might affect the correlation between PD and risk of hematological cancers (37). Second, we noted that the sample size was small and the results had a wide confidence interval in two studies (13,15), which limited the power of analyses. Moderate heterogeneity was detected among some subgroups. These analyses were not sufficiently powered owing to the limited number of studies included in the stratified groups. Thus, the subgroup results should be interpreted with caution. Finally, subgroup analysis revealed increasing severity of periodontitis was not associated with risk of hematopoietic and lymphatic cancers. Assessment methods of PD were heterogeneous in each study or the definitions for categories of PD severity varied between the included studies. Michaud *et al.*, 2018 reported assessment of PD based on both level of attachment loss and pocket depth measurements (18), Mai *et al.*, 2016 assessed PD severity using clinically measured alveolar crestal height (15), two studies used self-reported questionnaire for evaluating PD status (16,17), and two studies did not mention the procedures for assessment of PD (13,14), which might affect the heterogeneity and precision of our results.

The strengths of our pooled analysis are as follows. First, the meta-analysis is the first to exclusively explore the correlation of PD with risk of hematopoietic and lymphatic cancers. Second, we found low heterogeneity across studies for overall estimate, there was no publication bias. Subgroup and sensitivity analyses revealed consistent results for the relation of PD with risk of hematopoietic and lymphatic cancers, which imply the robustness and reliability of our findings. Third, most studies included in the meta-analysis were of high quality according to the predefined quality assessment criteria and controlled the major and common confounders (age, gender, body mass index, diabetes, and smoking). Four studies were prospective cohort studies (15-18), which minimized the recall and selection bias. Five studies have more than 15 years of follow-up (13,15-18). Sufficiently long follow-up (e.g. 5-10 years) is necessary because most human cancers have a long subclinical period (38,39).

In summary, our pooled analysis indicates that periodontitis is significantly associated with an increased risk of hematopoietic and lymphatic cancers, especially lymphatic cancers. Moreover, the associations are particularly strong in the population of never smokers and the American population. However, additional prospective studies with a larger inclusion population, improved measurement and classification of PD, longer follow-up duration, and well-designed clinical models

adjusted for the major and common confounders (e.g., age, gender, race, smoking status, body mass index, diabetes history) are warranted to confirm present findings. Additional research is expected to assess whether PD prevention and treatment can decrease the incidence of hematopoietic and lymphatic cancers. Findings of this meta-analysis highlight the importance of maintaining good oral health, which may lead to a reduced risk of developing hematopoietic and lymphatic cancers.

References

1. Beck JD, Offenbacher S. The association between periodontal diseases and cardiovascular diseases: a state-of-the-science review. *Ann Periodontol.* 2001;6:9-15.
2. D'Aiuto F, Gable D, Syed Z, Allen Y, Wanyonyi KL, White S, *et al.* Evidence summary: The relationship between oral diseases and diabetes. *Br Dent J.* 2017;222:944-8.
3. Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. *Nat Rev Rheumatol.* 2017;13:606-20.
4. Zeng XT, Xia LY, Zhang YG, Li S, Leng WD, Kwong JS. Periodontal Disease and Incident Lung Cancer Risk: A Meta-Analysis of Cohort Studies. *J Periodontol.* 2016;87:1158-64.
5. Chung JH, Hwang HJ, Kim SH, Kim TH. Associations Between Periodontitis and Chronic Obstructive Pulmonary Disease: The 2010 to 2012 Korean National Health and Nutrition Examination Survey. *J Periodontol.* 2016;87:864-71.
6. Yao QW, Zhou DS, Peng HJ, Ji P, Liu DS. Association of periodontal disease with oral cancer: a meta-analysis. *Tumour Biol.* 2014;35:7073-7.
7. Wang RS, Hu XY, Gu WJ, Hu Z, Wei B. Tooth loss and risk of head and neck cancer: a meta-analysis. *PLoS One.* 2013;8:e71122.
8. Zeng XT, Deng AP, Li C, Xia LY, Niu YM, Leng WD. Periodontal disease and risk of head and neck cancer: a meta-analysis of observational studies. *PLoS One.* 2013;8:e79017.
9. Chen H, Nie S, Zhu Y, Lu M. Teeth loss, teeth brushing and esophageal carcinoma: a systematic review and meta-analysis. *Sci Rep.* 2015;5:15203.
10. Maisonneuve P, Amar S, Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. *Ann Oncol.* 2017;28:985-95.
11. Ren HG, Luu HN, Cai H, Xiang YB, Steinwandel M, Gao YT, *et al.* Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis. *Ann Oncol.* 2016;27:1329-1336.
12. Michaud DS, Fu Z, Shi J, Chung M. Periodontal Disease, Tooth Loss, and Cancer Risk. *Epidemiol Rev.* 2017;39:49-58.
13. Kristinsson SY, Koshiol J, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, *et al.* Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenström macroglobulinemia. *J Natl Cancer Inst.* 2010;102:557-67.
14. Chung SD, Tsai MC, Huang CC, Kao LT, Chen CH. A population-based study on the associations between chronic periodontitis and the risk of cancer. *Int J Clin Oncol.* 2016;21:219-23.
15. Mai X, LaMonte MJ, Hovey KM, Freudenheim JL, Andrews CA, Genco RJ, *et al.* Periodontal disease severity and cancer risk in postmenopausal women: the Buffalo OsteoPerio Study. *Cancer Causes Control.* 2016;27:217-28.
16. Bertrand KA, Shingala J, Evens A, Birmann BM, Giovannucci E, Michaud DS. Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. *Int J Cancer.* 2017;140:1020-6.
17. Nwizu NN, Marshall JR, Moysich K, Genco RJ, Hovey KM, Mai X, *et al.* Periodontal Disease and Incident Cancer Risk among Postmenopausal Women: Results from the Women's Health Initiative Observational Cohort. *Cancer Epidemiol Biomarkers Prev.* 2017;26:1255-65.
18. Michaud DS, Lu J, Peacock-Villada AY, Barber JR, Joshi CE,

- Prizment AE, *et al.* Periodontal Disease Assessed Using Clinical Dental Measurements and Cancer Risk in the ARIC Study. *J Natl Cancer Inst.* 2018;110:843-54.
19. Barton MK. Evidence accumulates indicating periodontal disease as a risk factor for colorectal cancer or lymphoma. *CA Cancer J Clin.* 2017;67:173-4.
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6:e1000097.
21. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, *et al.* The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis, 2000.
22. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA.* 1998;280:1690-1.
23. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. *BMJ.* 2011;342:d671.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials.* 2015;45:139-45.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst.* 1959;22:719-48.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* 1997;315:629-34.
27. Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. *Lancet Oncol.* 2008;9:550-8.
28. Wen BW, Tsai CS, Lin CL, Chang YJ, Lee CF, Hsu CH, *et al.* Cancer risk among gingivitis and periodontitis patients: a nationwide cohort study. *QJM.* 2014;107:283-90.
29. Coussens LM, Werb Z. Inflammation and cancer. *Nature.* 2002;420:860-7.
30. Vendrame E, Hussain SK, Breen EC, Magpantay LI, Widney DP, Jacobson LP, *et al.* Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. *Cancer Epidemiol Biomarkers Prev.* 2014;23:343-9.
31. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. *Cell.* 2006;124:823-35.
32. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev.* 2007;16:405-8.
33. Meyer MS, Joshipura K, Giovannucci E, Michaud DS. A review of the relationship between tooth loss, periodontal disease, and cancer. *Cancer Causes Control.* 2008;19:895-907.
34. Hiraki A, Matsuo K, Suzuki T, Kawase T, Tajima K. Teeth loss and risk of cancer at 14 common sites in Japanese. *Cancer Epidemiol Biomarkers Prev.* 2008;17:1222-7.
35. Hwang IM, Sun LM, Lin CL, Lee CF, Kao CH. Periodontal disease with treatment reduces subsequent cancer risks. *QJM.* 2014;107:805-12.
36. Shi J, Leng W, Zhao L, Deng C, Xu C, Wang J, *et al.* Tooth loss and cancer risk: a dose-response meta analysis of prospective cohort studies. *Oncotarget.* 2018;9:15090-100.
37. Fitzpatrick SG, Katz J. The association between periodontal disease and cancer: a review of the literature. *J Dent.* 2010;38:83-95.
38. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. *J Surg Oncol.* 1997;65:284-97.
39. Shi T, Min M, Sun C, Zhang Y, Liang M, Sun Y. Periodontal disease and susceptibility to breast cancer: A meta-analysis of observational studies. *J Clin Periodontol.* 2018;45:1025-33.

Funding

The work was supported by Scientific Research Project of The Fifth People's Hospital of Shanghai, Fudan University (No. 2018WYZT05) and the Scientific Research Project of Shanghai Municipal Health and Family Planning Commission (No. 201740230).

Conflict of interest

All authors declare that they have no competing interests. Yougen Wu and Xiaojun Shi have contributed equally to the work. Therefore, both are co-authors of the paper.